Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 in advanced solid tumors
NCT03710265Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Nov 2018
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of retlirafusp alfa in solid tumor, sponsored by Hengrui. Primary endpoints: Safety and tolerability profile of SHR-1701 and Objective Response Rate up to 1 year. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03710265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710265.